CONTENTS

List of figures page xiv
List of tables xv
Foreword by Chief Justice Sundaresh Menon xvii
Preface xxii
Acknowledgements xxiv

1 Economic integration, Asia and medicines 1
1.1 Introduction – globalization and Asia 1
1.2 Aging Asia: healthcare needs 4
1.3 Diseases in Asia and the Pacific region 6
1.4 Poverty in Asia 8
1.5 The growth of National Health Expenditure 9
1.6 Medicines, R&D and Asia – an overview 16
1.7 Economic integration activities in Asia and health matters: an overview 22
1.8 TRIPS-plus requirements and Asia – an introduction 24
1.9 New legal risks – potential of investor-state claims 26
1.10 Syncopation between the law, science and social policy 26
1.11 The role of international organizations 27
1.12 The global and regional context 29
1.13 Economic reform and IPRs in Asia 41
1.14 Conclusion 44
2 Access to medicines, innovation and the debate at
the multilateral level 46
2.1 Globalization, trade and public health dimensions: The
context 46
2.2 Government reviews on the pharmaceutical sector and
patents 56
2.3 International patent commitments: from Paris to
Uruguay and beyond 57
2.4 The promise of TRIPS: flexibilities for members 58
2.5 Regulatory tensions 62
2.6 The place of patents in the debate 66
2.7 A very contentious debate 81
2.8 Other relevant elements of the debate 83
2.9 Conclusion 99

3 Trade, investment and medicines: the existing legal and
policy construct 101
3.1 The existing legal and policy construct 101
3.2 ASEAN – the need for greater clarity in the collective
legal and policy construct 103
3.3 Key elements 103
3.4 Exhaustion of rights and parallel imports 159
3.5 Conclusion 162

4 Treaties in Asia: embedded risks and lessons from disputes
elsewhere 164
4.1 Legal obligations in TRIPS 164
4.2 Examples of TRIPS disputes in the WTO
system 165
4.3 TRIPS-like and TRIPS-plus commitments in Asia
FTAs 167
CONTENTS

4.4 FTAs and legal risks arising from negotiated language 168
4.5 Non-FTA mechanisms with a bearing on national laws 172
4.6 Types of TRIPS-plus FTA provisions 172
4.7 The treaty-based ISDS system – legal risks and concerns 201
4.8 “Counterweight” provisions relevant to the regulation of the pharmaceutical industry 214
4.9 Conclusion 215

5 The importance of exceptions and flexibilities 219
5.1 Introduction 219
5.2 Exception provisions – general considerations 221
5.3 Applicability of GATT 1994 Article XX to WTO Accession Protocol commitments: lessons learnt 224
5.4 Safe harbours: Asian treaties’ general exceptions 225
5.5 TRIPS principles and objectives in FTAs 227
5.6 TRIPS exceptions and flexibilities 228
5.7 Using a non-violation provision to safeguard the use of exceptions and limitations 266
5.8 Investment treaty general exceptions and expropriation exceptions relevant to health 268
5.9 Security exceptions 273
5.10 Interpretational treaty signals 275
5.11 Negotiating space 277
5.12 Conclusion 281

6 Innovation and competition 283
6.1 Innovation, competition: seeking a balance 283
6.2 Patents and competition law – necessary bedfellows 286
6.3 Emerging case law on competition law and pharmaceutical patentees’ practices 289
6.4 The European Union: towards increased competition enforcement in pharmaceuticals sector 294
6.5 Asia’s first pay-for-delay case 297
6.6 Developments in other jurisdictions 298
6.7 Connecting refusals to licence patents and the essential facilities doctrine: the next logical step? 302
6.8 Competition law and the pharmaceutical sector in Asia – an evolving regional landscape 306
6.9 Conclusion 332

7 Setting new directions: the need for innovative legal and policy solutions 334
7.1 The need for new paradigms and strategies 334
7.2 A brief inventory of major initiatives 337
7.3 The evolving role of the state as a provider of incentives 342
7.4 The evolving paradigm in R&D: public-private partnerships to promote public health and innovation 344
7.5 Exploring new funding models 348
7.6 The evolving role of business 352
7.7 Rethinking clinical data protection 353
7.8 Treaty-based approaches 366
7.9 The use of differential or tiered pricing: affordable prices and facilitative aspects in trade and investment treaties 377
7.10 Dispute resolution provisions for public health 387
7.11 Conclusion 388

8 What next? 389

8.1 Advancing access: important questions and trends for Asia to consider 389
8.2 Clarifying critical matters in the multilateral trade system 389
8.3 New incentives – new ways of rewarding conduct that contributes to greater access 404
8.4 Timely evaluations and coherent policy-making in growing areas 405
8.5 Can industry do more? 411
8.6 Can governments do more? 418
8.7 Regional integration and pharmaceutical initiatives 422
8.8 Watch this space: BRICS and health 430
8.9 Encouraging new alliances and collaborations 432
8.10 Preparing for the debate ahead: legal education and capacity-building 435
8.11 Conclusion 436

Index 439